An interventional study of Melanocyte Keratinocyte Transplantation Procedure (MKTP) and Jodhpur Technique in Leukoderma, sponsored by Al-Azhar University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
This study aims to compare the efficacy and safety of Melanocyte Keratinocyte Transplantation Procedure (MKTP) combined with 308-nm excimer laser versus Jodhpur technique combined with 308-nm excimer laser in the treatment of stable non-vitiligo leukoderma. Twenty-two patients with stable depigmented lesions will be enrolled. In each patient, two comparable lesions will be treated using different techniques. Clinical outcomes including percentage of repigmentation, color match, time to onset of repigmentation, complications, and histological changes will be assessed during follow-up to determine the optimal surgical treatment approach for non-vitiligo leukoderma.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
This study's planned enrollment of 22 is below the median of 36 across 265 interventional studies indexed under Vitiligo.
Browse Vitiligo studies →Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Melanocyte Keratinocyte Transplantation Procedure followed by 308-nm excimer laser therapy
Procedure: Melanocyte Keratinocyte Transplantation Procedure (MKTP) · Device: 308-nm Excimer Laser
Jodhpur technique followed by 308-nm excimer laser therapy
Procedure: Jodhpur Technique · Device: 308-nm Excimer Laser
Autologous melanocyte-keratinocyte cell suspension prepared using enzymatic separation and applied to a dermabraded recipient site.
Autologous non-cultured epidermal cell transfer technique using dermabraded donor skin particles applied directly to the recipient site without enzymatic processing
Excimer laser therapy initiated approximately 14 days after surgery, administered twice weekly for 12-16 weeks with dose adjustment according to erythema response
Mean Percentage Repigmentation of Target Lesions
Time frame: 6 months
Time to Onset of Repigmentation
Time frame: Up to 6 months
Color Match Assessment
Time frame: 6 months
No study locations are listed for this record.
Start is estimated for Jul 2026; primary completion for Jul 2026, 0 months later.
Of 63 non-industry interventional studies with no phase under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 0 months is below that.
Counting every sponsor, half of 67 studies reached it within 17 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.